research Adverse effect profile with low-dose methotrexate therapy in patients suffering with rheumatic diseases
Low-dose methotrexate is generally safe but can cause mild to severe side effects, and folic acid can reduce these risks.
Search
for
Sort by
Research
30-60 / 1000+ results 
research Severe Alopecia caused by Azathioprine in Systemic Lupus Erythematosus.
Azathioprine can cause severe hair loss and low white blood cell count in lupus patients.
research Drug points: Remission of alopecia universalis during sulphasalazine treatment for rheumatoid arthritis
A woman's hair grew back while she was taking sulphasalazine for arthritis.
research AB0597 Comparative analysis of safety data of four treatment regimens in early rheumatoid arthritis patients
Methotrexate plus prednisolone had the fewest serious side effects.
research Tofacitinib for the Treatment of Three Immune-mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata
Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
research USE OF UPADACITINIB IN 2 CASES OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
research Relapsing Course of Sulfasalazine-Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Complicated by Alopecia Universalis and Vitiligo
Sulfasalazine can cause severe allergic reactions leading to long-term autoimmune issues like hair loss and skin discoloration.
research Anifrolumab for systemic lupus erythematosus: A clinical study of Japanese patients in Kanazawa University Hospital
Anifrolumab effectively improved symptoms and reduced steroid use in Japanese patients with systemic lupus erythematosus.
research P14 Mycophenolate mofetil in patients with autoimmune hepatitis intolerant to azathioprine
Mycophenolate mofetil is a good alternative for autoimmune hepatitis patients who can't tolerate azathioprine.
research Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis
Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.
research Local infusion of infliximab for the treatment of acute joint inflammation
Co-trimoxazole may help treat autoimmune diseases.
research Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.
research Leflunomide: an unlikely trigger and mechanistically a beneficial drug for alopecia areata
Leflunomide is more likely to help treat alopecia areata than cause it.
research Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions
Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.
research Teriflunomide in multiple sclerosis: an update
Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
research THE USE OF TOFACITINIB IN THE TREATMENT OF IMMUNE-MEDIATED UNIVERSAL ALOPECIA IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A CASE REPORT
Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.
research An urticarial drug eruption caused by tofacitinib for alopecia universalis
A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
research Diclofenac/imiquimod
Some elderly men had healing problems after using imiquimod and diclofenac for skin conditions on their scalps.
research P133 Anifrolumab treatment improves quality of life and decreases corticosteroid use in patients with SLE
Anifrolumab improves quality of life and reduces steroid use in SLE patients.
research P075 A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata
Tofacitinib was more effective than methotrexate for treating alopecia areata.
research P0881 Effectiveness and Safety of Tofacitinib in Biologic-Naïve Elderly Patients with Ulcerative Colitis
Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
research Two cases in which tofacitinib effectively treated both ulcerative colitis and alopecia areata
Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.
research BH06 (P075) A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata
Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
research Comparison of efficacy and safety of tofacitinib and azathioprine in patients with alopecia areata and variants: a double-blind, randomized controlled trial
research NUDT15 polymorphism explains serious toxicity to azathioprine in Indian patients with chronic immune thrombocytopenia and autoimmune hemolytic anemia: a case series
The NUDT15 gene variant causes severe side effects from azathioprine in some Indian patients.
research 08.33 Treatment of rheumatoid arthritis patients: comparative efficacy of four treatment regimens
MTX and GC combinations are the most effective for early rheumatoid arthritis.
research Hair Loss in a Hemodialysis Patient after Repetitive Use of the Antipruritic Drug Nalfurafine: Implications of Impaired Angiogenesis for Hair Loss
Stopping nalfurafine reversed hair loss in a hemodialysis patient.
research Romatoid Artritli Hastalarda Metotreksat Toksisitesini Önlemede Yüksek Doz Günlük Folat Desteğine Karşın Düşük Doz Haftalık Folat Desteğinin Etkileri
Weekly 5 mg folate is enough to prevent methotrexate toxicity in rheumatoid arthritis patients.
research Methotrexate for maintenance of remission in ulcerative colitis
Methotrexate is not proven to maintain remission in ulcerative colitis.
research P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.